Laikind takes charge of Burnham's business development

The former CEO of Metabasis, Paul Laikind, is taking on the job of commercializing the work done at the Burnham Institute for Medical Research. Laikind was named senior vice president of business development and chief business officer at the institute, where he will work to cultivate new business relations in the biopharma world. Report

Aileron Therapeutics has named Steven Kafka as its chief financial officer and vice president of finance and operations. Report

NovaBay Pharmaceuticals has named Mark Anderson, Ph.D. as chief scientific officer, a new position for the company.  Release

Symphogen A/S said that Jørgen Petersen, M.D., DMSc, has joined the company`s executive management team as chief development officer. Dr. Petersen comes to Symphogen from Genmab A/S. Release

ThermoGenesis has named Jorge F. Artiles as vice president, chief quality and regulatory affairs officer. Release

ZephyrBiotech LLC has added Victoria Sergeant as partner. Release

Peregrine Pharmaceuticals announced that Dr. Robert Garnick has joined the company as the head of regulatory affairs. Release

Premier Research Group Limited named Bernard Sweeney as executive director, medical devices. Release

Epizyme announced that Dr. Hoyoung Huh, president and CEO of BiPar Sciences, was appointed Epizyme's chairman of the board of directors. Epizyme recently announced the closing of a $32M Series B financing led by Bay City Capital. Release

Aastrom Biosciences announced that Harold C. Urschel, Jr., M.D., has been elected to the company's board of directors. Release

Gail Maderis has joined the board of Trinity Biosystems. Release

Shrink Nanotechnologies announced that Bruce R. Conklin, M.D., a senior investigator at the Gladstone Institute and Professor of Medical Genetics and Cellular and Molecular Pharmacology at the University of California San Francisco, and Dr. Kara McCloskey, Professor at the School of Engineering, University of California, Merced, have joined its Scientific Advisory Board. Release

Pacific Biosciences has named Evan Eichler, Ph.D. to its Scientific Advisory Board. Release

Cytochroma has appointed John Cunningham, CVO, BM BCh, DM, FRCP, to the Company's Scientific Advisory Board. Release

Suggested Articles

Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.

After a rough patch in 2017, the stars seem to be realigning for French CAR-T expert Cellectis, which just closed a $164 million U.S. public offering.

Investment firm Frazier Healthcare Partners has closed its 11th fund—worth $780 million—that will help established companies accelerate their growth.